Background. Congenital heart lesions may be complicated by pulmonary arterial smooth muscle hyperplasia, hypertrophy, and hypertension. We assessed whether inhaling low levels of nitric oxide (NO), an endothelium-derived relaxing factor, would produce selective pulmonary vasodilation in pediatric patients with congenital heart disease and pulmonary hypertension. We also compared the pulmonary vasodilator potencies of inhaled NO and oxygen in these patients.
C ongenital heart lesions that increase pulmonary blood flow1 or cause pulmonary venous ob-struction2 may produce pulmonary artery smooth muscle hypertrophy and hyperplasia3 and pulmonary vasoconstriction. Current drug therapies for pulmonary artery hypertension are nonselective and dilate systemic blood vessels. Unless surgical correction of the underlying congenital heart lesion occurs early in life, pulmonary vasoconstriction may persist, progress to vascular obliteration, and produce a high morbidity. 4 Nitric oxide (NO), which has identical activity as endothelium-derived relaxing factor,5.6 is produced from L-arginine7 by endothelial NO synthase.8 NO diffuses into subjacent vascular smooth muscle and mediates vasodilation by stimulating soluble guanylate cyclase to produce cyclic GMP (cGMP).910 Inhaling low levels of NO reverses hypoxic pulmonary vasoconstric- and reduces pulmonary vascular resistance in adults with primary pulmonary hypertension13 and the adult respiratory distress syndrome. 14 We have reported that inhaling 80 ppm NO for 30 minutes increases preductal and postductal oxygenation in infants with persistent pulmonary hypertension of the newborn.15 NO diffuses into the intravascular space, where it rapidly binds to hemoglobin, becoming inactivated and thereby prohibiting systemic vasodilation. This reaction leads to the formation of methemoglobin. 16 In the present study, we demonstrate that inhaling NO for brief periods selectively reduces pulmonary vasoconstriction in pediatric patients with congenital heart disease complicated by pulmonary artery hypertension. We also compare the pulmonary vasodilatory effectiveness of low concentrations of inhaled NO with oxygen breathing in pediatric patients with congenital heart disease undergoing cardiac catheterization.
Methods
These investigations were performed with approval by the subcommittees for human studies of the Massachusetts General Hospital and an IND approval by the US Food and Drug Administration. Informed consent was obtained from the parents of our patients. Nitric Oxide Delivery System NO gas (800-1,000 ppm in N2, Airco, Riverton, N.J.) was mixed with N2 using a standard low-flow blender (Bird Blender, Palm Springs, Calif.). The NO and N2 gas mixture was then mixed with varying quantities of air and oxygen shortly before introduction into the 1-1 reservoir of a pediatric nonrebreathing mask (Baxter Healthcare Corp., Valencia, Calif.) worn by the patient. This system allowed separate regulation of the inspired concentrations of NO as quantified by chemilumines-cence17 (model 14A, ThermoEnvironmental Instruments Inc., Franklin, Mass.) and oxygen (Hudson Oxygen Meter 5590, Temecula, Calif.). The total gas flow rate was maintained above 8 1 min-', which reduced the NO residence time within the breathing circuit and hence the time for oxidation of NO to NO2. The stock NO gas contained up to 1% of the nitrogen oxides as NO2 (e.g., 800 ppm NO stock gas contained less than 8 ppm NO2); the inspired NO2 concentration did not exceed 5% of the NO level. Exhaled gases, as well as those discharging from the chemiluminescence instrument, were scavenged.
Patient Studies
During diagnostic cardiac catheterization, we investigated separately the hemodynamic effects of inhaling low levels (20-80 ppm) of NO and a high FIo2 by 10 successively studied, spontaneously breathing pediatric patients with congenital heart disease complicated by pulmonary hypertension. After sedation and placement of vascular catheters under local anesthesia, the specific cardiac lesions were defined with standard hemodynamic measurements and angiographic techniques. Pulmonary and femoral arterial blood pressures were determined with indwelling catheters and fluid-filled transducers (model 1280C, Hewlett-Packard, Palo Alto, Calif.). In patients with intracardiac shunting (patients 1-6; Tables 1 and 2), pulmonary and systemic blood flows were determined by measuring oxygen consumption (MRM-2, Waters Instruments, Rochester, Minn.),18 calculating pulmonary artery and pulmonary vein oxygen content from Pao2 and hemoglobin oxygen saturation complete atrioventricular canal; PV, pulmonary vein; MR, mitral (Radiometer, Copenhagen), and using the Fick principle. In patients without an angiocardiographically demonstrated intracardiac shunt, cardiac output was determined in triplicate utilizing the thermodilution technique of injecting 3-ml aliquots of 0°C normal saline (COM-2, Baxter, Irvine, Calif.). Vascular resistance and central shunt were determined with standard formulae, and resistance was indexed to body surface area. '9 In the 10 successive patients with pulmonary artery hypertension defined by an initial peak pulmonary artery pressure of more than half the systolic arterial pressure, the hemodynamic response to 10-minute periods of breathing at FiO2 0.9 with or without inhaling low levels of NO was determined. In the first seven patients treated (excluding patients 2, 3, and 6), the response of the pulmonary circulation to 10-minute periods of sequentially inhaling 0, 20, 40, and 80 ppm NO at FiO2 0.9 was determined. In the last eight patients studied, the hemodynamic effects of inhaling 80 ppm NO at FiO2 0.21 were determined. In the six patients with an intracardiac shunt (patients 1-6), pulmonary and systemic blood flows were determined while breathing at FiO2 0.21 and at FiO2 0.9 with and without 80 ppm NO. Arterial blood was obtained for optical determination of methemoglobin levels20 before and at the completion of the study.
All values are presented as mean+ SD. ANOVA with repeated measures was utilized; a posteriori testing was performed using a Fisher's protected least significant difference test.2' In comparing the patients with Trisomy 21 with others, a one-tailed Student's t test was used. 21 Significance is judged at a 5% level.
Results
A total of 10 patients (age range, 3 months to 6.5 years) were studied (Table 1) . Six patients (patients 1-6) had increased pulmonary blood flow due to a ventricular septal defect (VSD) or complete atrioventricular canal (AVC), and two patients had pulmonary venous hypertension. One patient had pulmonary hypertension after repair of a VSD and pulmonary vein stenosis, and one had pulmonary hypertension associ-ated with a hemodynamically insignificant VSD. Of the five patients with Trisomy 21, three had a complete AVC (one of which was corrected), and two had a VSD. All 10 patients had pulmonary hypertension with a baseline mean pulmonary artery pressure of 48±19 mm Hg and pulmonary vascular resistance index (Rp) of 658±421 dyne * sec * cm`* m-2 ( Table 2 ). The mean pulmonary artery pressure of the five patients with Trisomy 21 was 60±19 mm Hg and higher than that of the other five patients whom we studied (p<0.05). In the six patients with an intracardiac shunt, the pulmonary-to-systemic blood flow ratio was 2.0±0.8. Except for patient 10, who chronically breathed at FIo2 0.30, nine patients were breathing room air. The baseline pHa and Paco2 values were within the normal range (Table 1 ) and did not change during the study (p>0.05). Breathing at FiO2 0.9 increased Pao2 to 292±83 mm Hg; breathing 80 ppm NO at FiO2 0.9 produced a Pao2 of 287±119 mm Hg (p>0.05). Approximately two thirds of the patients were chronically treated with digoxin; daily diuretic therapy was given to half of the patients. The baseline hematocrit was 37±5%.
The dose-response of pulmonary hemodynamics to 0-80 ppm inhaled NO at FiO2 0.9 was determined in seven patients. Adding NO to the hyperoxic gas mixture decreased Rp in a dose-dependent manner (Figure 1 ). Breathing 40 ppm NO at FiO2 0.9 significantly decreased Rp below both baseline and hyperoxic levels (pO0.05).
The maximum reduction of Rp was achieved by inhaling 80 ppm NO at FiO2 0.9. We therefore used 80 ppm NO to determine the hemodynamic effects of inhaled NO at FiO2 0.21-0.3 or 0.9.
Inhaling 80 ppm NO at FiO2 0.21-0.3 or 0.9 rapidly reduced mean pulmonary artery pressure and Rp below the baseline level (pcO.05). However, pulmonary artery hypertension returned within minutes of cessation of NO inhalation. In patients with an intracardiac shunt (patients 1-6), inhaling 80 ppm NO at FiO2 0.21 modestly elevated pulmonary blood flow from 8.8±5.2 to 13.4±8.7 0.91 min* m-2 (p>0.05). Breathing 80 ppm NO at FiO2 0.9 significantly elevated pulmonary blood flow to 15.7±7.8 1l min-* m-2 and pulmonary-to-systemic blood flow ratio from 2.0±0.8 to 4.7±2.5 (both p<O.OS) ( Figure 2 ). Although the greatest reduction in Rp occurred while inhaling 80 ppm NO at FiO2 0.21-0.30 in patients with high baseline levels of Rp, when breathing NO at FiO2 0.90, eight of 10 patients exhibited a reduction in Rp (Table 2 and Figure 3 ). Each of the patients with Trisomy 21 had reduced mean pulmonary artery pressure and Rp values when measured during NO inhalation at FiO2 0.21-0.90.
In contrast to inhaling NO, breathing at FiO2 0.9 without added NO did not reduce mean pulmonary artery pressure but did reduce Rp to 535±379 dyne * sec * cm-5 m2 (p<0.05). In patients with an intracardiac shunt, breathing at FiO2 0.9 without added NO increased pulmonary blood flow from 8.8±5.2 to 15±7.8 1. min`1 m2 (pcO.05, Figure 2 ). For patients without an intracardiac shunt, breathing at FiO2 0.9 without added NO only modestly elevated pulmonary blood flow (Table 2) .
Although inhaled NO was a potent pulmonary vasodilator in eight of 10 pediatric patients with pulmonary 0.9 did not produce systemic vasodilation and did not alter mean aortic pressure, systemic blood flow, or systemic vascular resistance index (Rs). Inhaling up to 80 ppm NO for 30 minutes did not change the circulating methemoglobin levels (0.7±0.7% before NO, 0.7±0.4% after NO; n=7,p=0.53).
Discussion
In our studies of 10 pediatric patients with congenital heart disease and pulmonary artery hypertension, inhaling 80 ppm NO at either the baseline FiO2 (0.21-0.30) or at FIo2 0.9 reduced pulmonary vascular resistance and pulmonary artery pressure within 1-3 minutes without decreasing systemic arterial pressure or resistance ( Table 2 ). In each of our patients, within minutes after cessation of NO inhalation, pulmonary vascular resistance and pulmonary artery pressure returned to baseline levels. We found that inhaling 80 ppm NO at FiO2 0.9 produced the maximum reduction of Rp in eight of our 10 patients and increased pulmonary blood flow in all six patients with an intracardiac shunt (Figures 2 and 3 ). In contrast, breathing at FiO2 0.9 without NO did not reduce mean pulmonary artery pressure below baseline values and produced only a modest decrease of Rp compared with baseline measurements ( Figure 3 ). Thus, inhaling NO can dilate pulmonary vasoconstriction that is not caused by hypoxia in congenital heart disease.
The patients in our study with the greatest level of pulmonary hypertension or pulmonary vascular resistance had the most consistent reduction of mean pulmonary artery pressure and Rp with NO inhalation. Many of these patients also had Trisomy 21. Other investigators have reported that patients with Trisomy 21 and congenital heart disease exhibit the highest levels of pulmonary hypertension22,23 and that 90% of patients with Trisomy 21 presenting for diagnostic cardiac catheterization will have significant pulmonary hypertension.22 Although only 5% of pediatric patients with congenital heart disease who undergo cardiac catheterization have Trisomy 21,23 approximately half of the pediatric patients with congenital heart disease and pulmonary artery hypertension have Trisomy 21.22,24 Congenital heart lesions can produce pulmonary artery hypertension with vascular smooth muscle hyperplasia and hypertrophy.3 After corrective cardiac surgery, the pulmonary vascular bed in some patients with congenital heart diseases may not regress sufficiently to accommodate the postoperative hemodynamic changes. It often is desirable to determine the vasodilatory capacity of the pulmonary circulation during preoperative cardiac catheterization to attempt to predict the postoperative pulmonary vascular resistance. Hyperoxic breathing has been used to determine the vasodilatory capacity of the lung. Currently used vasodilator agents such as prostacyclin (PGI2),25 tolazoline,26 prostaglandin E1,27 and sodium nitroprusside27 may reduce the pulmonary vascular resistance. However, these intravenous agents are nonselective and dilate the systemic circulation.25,27-29 Thus, we chose to compare the pulmonary vasodilator potency of inhaled NO with oxygen as it is the only other pulmonary vasodilator in widespread use that does not cause systemic vasodilation. This study demonstrates that inhaled NO is a selective pulmonary vasodilator that exhibits a far greater vasodilatory effect than hypertension. inhaling 80 ppm NO at both FiO2O.21 and tp<0.05 value differs from FiO2 0.9 without inhaled NO. hyperoxic breathing. A much larger study correlating the effects of preoperative inhaled NO with postoperative hemodynamic course should be performed in the future.
Our study demonstrates that inhaled NO is a potent pulmonary vasodilator. There are two recent reports comparing the pulmonary vasodilatory effects of intravenous prostacyclin with inhaled NO in two adult patient populations: adults with primary pulmonary hyperten-sion13 and adult respiratory distress syndrome.14 Despite the differences in etiology of the pulmonary vascular hypertension in these two syndromes, inhaled NO produced more consistent pulmonary vasodilation than PGI2, without causing systemic vasodilation.
The pulmonary and systemic vasodilation produced by intravenous prostacyclin has been extensively studied in congenital heart disease. Bush et a125 evaluated the pulmonary vasodilatory potency of intravenous PGI2 in 20 pediatric patients with congenital heart disease and a Rp (p=0.65, unpaired t test) and mean pulmonary artery pressure (p=0.98) similar to those of the patients whom we studied. Bush and coworkers reported that intravenous infusions of 20 ng . kg`min`PGI2 reduced Rp by 186 dyne. sec * cm`5 m-2 when the patients breathed at FiO2 0.21, and PGI2 reduced Rp by 136 dyne. sec. cm`5 * m2 when the patients breathed at FiO2 1.0. In comparison with this study of intravenous prostacyclin, we found 24% and 70% greater reduction of Rp when 80 ppm NO was breathed at FiO2 0.21-0.3 and 0.9, respectively, in contrast to PGI2. This indirect comparison suggests that inhaled NO may produce more potent and selective pulmonary vasodilation than PGI2 in pediatric patients with congenital heart disease.
Studies of patients with pulmonary hypertension following congenital heart surgery reported a reduction of mean pulmonary artery pressure during treatment with intravenous nitroprusside, a NO donor compound.29 Inhaled NO diffuses directly into pulmonary vascular smooth muscle cells and activates guanylate cyclase9.10 to produce vasodilation. NO that diffuses into the pulmonary circulation is rapidly inactivated by combination with hemoglobin, thereby preventing systemic vasodilation. Our laboratory has reported selective pulmonary vasodilation by NO inhalation in sheep weighing 25-35 kg with pulmonary vasoconstriction produced by hypoxia or infusion of a stable thromboxane analogue (U46619)11; NO vasodilation was not altered by indomethacin treatment, suggesting prostacyclin production was not involved. 30 Recently, we reported that inhaled NO is a pulmonary vasodilator that rapidly and completely reverses hypoxic pulmonary vasoconstriction without producing systemic hypotension in the newborn lamb with a transitional circulation. 31, 32 We also re- by seven pediatric patients with congenital heart disease. tp<0.OS value differsfrom both baseline and FIO2 0.9 without inhaled NO. Increasing the FIO2 from baseline (0.21-0.3) to 0.9 did not change Rp. Adding 40ppm NO reduced Rp below both baseline and Fio2 0.9 levels; the maximal pulmonary vasodilatory effect was obtained by breathing 80 ppm NO in oxygen.
It is likely that there is no toxicity associated with breathing 20-80 ppm NO for the brief period of a cardiac catheterization. No pulmonary injury, which is more likely to be associated with NO2 inhalation, was apparent in our patients. Recently, seven patients with severe adult respiratory distress syndrome were treated by inhaling 20 ppm NO for 11-53 days with a consis-6p 30 1.min1.lm 2 251 _t .14 FIGURE 2 . Bar graphs ofhemodynamic effects ofbreathing at FRo2 0.9 and 80 ppm NO by six pediatric patients with congenital heart disease and an intracardiac shunt. Units for bloodflow (Q) are 1 min' * m 2. tp<0.05 value differs from Fio2 0.21 without NO. *p<0.05 value differs from FIO2 0.21 with 80 ppm NO. Breathing 80ppm NO at FRo2 0.9 increased pulmonary blood flow (Qp). Inhaling 80 ppm NO at FIo2 0.21-0.3 and 0.9 did not alter systemic blood flow (Q). Breathing at FRO2 0.9 with or without 80 ppm NO increased QpIQs. Maximum elevation of QplQ. occurred while inhaling 80 ppm NO at Fio2 0.9. 
